Special premium report Part 1: My 2018 earnings boom profit strategy–and two picks
With the report of first quarter earnings season from Netflix (NFLX) on Monday, April 16, we’ve moved into the heart of earnings season. In most quarters traders began putting on plays for earnings announcements a few weeks before reporting starts. And they’ll keep making new bets over the next three weeks or so. In most quarters buying shares or options on companies about to report makes profitable sense. But this strategy is likely to be even more rewarding this year
So how volatile is this stock market? There’s more fear out there than the usual measures suggest
Last week gave us a decent read on how volatile this U.S. stock market is. And how fear and uncertainty rule this market. Let me use the Freeport McMoRan Copper & Gold (FCX) May 18, 2018 puts with a strike price of $18 that I added to my Volatility Portfolio on April 3 as an example.
We’re inching toward earnings season: Do investors dare to get excited?
When it arrives, first quarter earnings season is going to be spectacular. At least that’s what Wall Street is now expecting. The consensus analyst estimate points to 16.9% year over year jump in earnings for the first quarter. (According to Wall Street estimates, the story for earnings growth in 2018 only gets better from there with 19.6%, 21.6% and 17.6% year over year earnings growth projected for the second, third, and fourth quarters of 2018, respectively.
FDA sets next date for Incyte arthritis drug, baricitinib
The Food and Drug Administration today announced that its Arthritis Advisory Committee will meet on April 23 to discuss the application by Incyte (INCY) and Eli Lilly (LLY) for approval of baricitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis
Leveraging near-term Incyte catalysts by adding call options to Volatility Portfolio
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Nektar blows away revenue projections, gives very positive guidance on drug pipeline
Shares of Nektar Therapeutics (NKTR) finished up 21.67% today to $102.87 after the biotech company announced after the close yesterday a smaller than expected fourth quarter 2017 loss of 21 cents a share (versus the Wall Street consensus projection of a 36 cents a...Adding Pioneer Natural Resources call options for January 18, 2019 at $180 to my Volatility Portfolio
I'm adding call options in a Permian Basin oil shale producer, Pioneer Natural Resources (PXD). I think the oil market is a good candidate for disruption in 2018 either from OPEC's efforts to drive the price of oil above $70 or from an outbreak of conflict in the...
Selling MGM March 16 calls out of my Volatility Portfolio
Shares of MGM Resorts International (MGM) rose 2.52% on Friday, February 23, to close at $35.38. I'm going to use that move to the upside to sell my March 16, 2018 MGM calls (MGM180316C00033000) out of my Volatility Portfolio. I bought these options back on September...
Buying call Nektar options at $90 for August 17, 2018 expiration in my Volatility Portfolio
When I started my rebalancing of my Volatility Portfolio on February 20, I thought I would add the slightly in the money Nektar Therapeutics (NKTR) calls at $80 with an expiration of August 17, 2018 at a closing price of $18.50. But the underlying stock has moved up...
To rebalance my Volatility Portfolio I’m selling my Nektar May 18 call options
I'm not complaining, mind you. As of Friday February 23, the Nektar Therapeutics May 18, 2018 call options with a strike of $26 (NKTR180518C00026000) in my Volatility Portfolio were up 2546% from my November 1, 2017 buy at $2.40 to $63.50. But I don't want to have...
